Press Releases
The role of CDOs in complex biologics development
In response to the continuous transformation in complex modalities, an integrated drug-development platform has been newly brought up to drug developers wanting to create an optimal set-up for successful manufacturing of their hard-developed drugs.
At the forefront of this transformation are antibody-based therapeutics, such as bispecific antibodies (BsAbs). The introduction of novel, intricate antibody-based therapeutics into the drug pipeline presents opportunities to effectively treat more patients. However, the advancement of novel biologics also introduced development and manufacturing difficulties that emphasize the need for flexible solutions with the ability to overcome complexity.
In this article, Jiseon Oh, Lead Scientist in Formulation Development at Samsung Biologics, discusses the role of contract development organization (CDO) partnerships in successfully progressing complex biologics from clinic to commercialization. She underscores the importance of integrating innovative technologies early in the process and using proprietary development platforms to overcome challenges without compromising quality or delaying timelines.
In response to the continuous transformation in complex modalities, an integrated drug-development platform has been newly brought up to drug developers wanting to create an optimal set-up for successful manufacturing of their hard-developed drugs.
At the forefront of this transformation are antibody-based therapeutics, such as bispecific antibodies (BsAbs). The introduction of novel, intricate antibody-based therapeutics into the drug pipeline presents opportunities to effectively treat more patients. However, the advancement of novel biologics also introduced development and manufacturing difficulties that emphasize the need for flexible solutions with the ability to overcome complexity.
In this article, Jiseon Oh, Lead Scientist in Formulation Development at Samsung Biologics, discusses the role of contract development organization (CDO) partnerships in successfully progressing complex biologics from clinic to commercialization. She underscores the importance of integrating innovative technologies early in the process and using proprietary development platforms to overcome challenges without compromising quality or delaying timelines.